Abstract: The invention relates to method of treatment using fusion proteins. The fusion proteins may be RAGE fusion proteins produce by methods for controlling the glycosylation of the fusion protein. The fusion protein may comprise a RAGE polypeptide linked to an immunoglobulin polypeptide.

Abstract: The invention relates to methods for controlling the glycosylation of a RAGE fusion protein. The invention also relates to compositions comprising an amount of a RAGE fusion protein where at least 0.5% of the amount of the RAGE fusion protein is aglycosylated and wherein no more than 53.2% of the amount of the RAGE fusion protein is aglycosylated.

Abstract: The invention relates to novel methods for controlling the glycosylation of a protein and the protein produced thereby. An exemplary method of the invention comprises producing a protein comprising a decreased level of glycosylation, e.g., the protein comprises fewer glycans or fewer saccharides at the glycosylation site, by culturing a host cell expressing the protein in the presence of a glycosylation inhibitor. In an exemplary method of the invention, the biological characteristics of the protein are altered by the decreased level of glycosylation, e.g., the binding of the protein with its target ligand is modified.